Brenzavvy®, an FDA-approved SGLT2 inhibitor, is designed to lower blood sugar levels in adults with type 2 diabetes, along with diet and exercise. The medication is the lowest priced sodium-glucose cotransporter 2 (SGLT2) compared to other drugs in the SGLT2 class. The price point makes SGLT2 therapy available for a large number of people who otherwise might not be able to afford to start and stay on this medication, namely those who are uninsured, underinsured, or on Medicaid.
Brenzavvy presents an affordable way for your patients to improve their health. It also presents an easy way for you to improve your financial health.